Scarica l'app Stockscreener
19.07
5.27%
-1.06
Dopo l'orario di chiusura:
19.04
-0.03
-0.16%
Precedente Chiudi:
$20.13
Aprire:
$20
Volume 24 ore:
5.11M
Relative Volume:
1.84
Capitalizzazione di mercato:
$2.22B
Reddito:
$631.73M
Utile/perdita netta:
$-239.78M
Rapporto P/E:
-9.4406
EPS:
-2.02
Flusso di cassa netto:
$-33.45M
1 W Prestazione:
+22.56%
1M Prestazione:
+38.49%
6M Prestazione:
+133.41%
1 anno Prestazione:
+24.64%
Intervallo 1D:
$18.90
$20.34
Intervallo di 1 settimana:
$15.42
$20.34
Portata 52W:
$6.78
$20.34
10 X Genomics Inc Stock (TXG) Company Profile
Nome
10 X Genomics Inc
Settore
Industria
Telefono
(925) 401-7300
Indirizzo
6230 STONERIDGE MALL ROAD, PLEASANTON, CA
Confronta TXG con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TXG
10 X Genomics Inc
|
19.07 | 2.55B | 631.73M | -239.78M | -33.45M | -2.02 |
|
VEEV
Veeva Systems Inc
|
239.95 | 38.75B | 3.08B | 860.33M | 1.33B | 5.1481 |
|
TEM
Tempus Ai Inc
|
76.84 | 13.53B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
HQY
Healthequity Inc
|
105.44 | 8.93B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
36.98 | 6.98B | 906.14M | -52.62M | 89.62M | -0.3621 |
|
DOCS
Doximity Inc
|
51.07 | 9.40B | 550.17M | 201.35M | 232.07M | 1.00 |
10 X Genomics Inc Stock (TXG) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-11 | Iniziato | Piper Sandler | Neutral |
| 2025-02-13 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-09-03 | Iniziato | Leerink Partners | Outperform |
| 2024-07-22 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-07-18 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-07-10 | Downgrade | Deutsche Bank | Buy → Hold |
| 2024-06-27 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-06-03 | Ripresa | Jefferies | Hold |
| 2024-05-01 | Downgrade | TD Cowen | Buy → Hold |
| 2023-12-14 | Iniziato | Guggenheim | Buy |
| 2023-12-13 | Iniziato | Wolfe Research | Outperform |
| 2023-12-12 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2023-07-05 | Ripresa | JP Morgan | Overweight |
| 2023-05-10 | Iniziato | Barclays | Overweight |
| 2023-03-31 | Iniziato | Stephens | Overweight |
| 2023-02-02 | Iniziato | UBS | Neutral |
| 2022-12-14 | Iniziato | Deutsche Bank | Buy |
| 2022-08-18 | Downgrade | Goldman | Neutral → Sell |
| 2022-07-25 | Iniziato | Canaccord Genuity | Buy |
| 2022-07-15 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-07-15 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-09-14 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-03-15 | Iniziato | William Blair | Outperform |
| 2020-12-02 | Iniziato | Goldman | Neutral |
| 2020-09-09 | Iniziato | Morgan Stanley | Overweight |
| 2020-07-10 | Iniziato | Stifel | Buy |
| 2020-03-05 | Iniziato | Guggenheim | Buy |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2019-10-07 | Iniziato | BofA/Merrill | Buy |
| 2019-10-07 | Iniziato | Cowen | Outperform |
| 2019-10-07 | Iniziato | JP Morgan | Overweight |
| 2019-09-24 | Iniziato | Evercore ISI | Outperform |
Mostra tutto
10 X Genomics Inc Borsa (TXG) Ultime notizie
BrightSpring Health Services, 10x Genomics, QuidelOrtho, Medpace, and Fortrea Shares Are Soaring, What You Need To Know - Finviz
CEO Saxonov Files To Sell 13,096 Of 10X Genomics Inc [TXG] - TradingView
10x Genomics, Inc.Common Stock (NQ: TXG - Markets Financial Content
10X Genomics stock hits 52-week high at 17.7 USD By Investing.com - Investing.com India
10X Genomics stock hits 52-week high at 17.7 USD - Investing.com
Spatial Biology Market Analysis and Forecast, 2025-2035: - GlobeNewswire
Spatial Biology Market Analysis and Forecast, 2025-2035: Stellaromics, RareCyte, and 10x Genomics Drive Innovation and Funding Momentum - Yahoo Finance
How 10x Genomics Inc. (1KJ) stock trades pre earnings2025 Support & Resistance & Reliable Breakout Forecasts - newser.com
Total liabilities & shareholders' equities of 10x Genomics Inc Class A – HAM:1KJ - TradingView
Is 10x Genomics Inc. stock a buy before product launchesJuly 2025 Closing Moves & Safe Entry Zone Tips - newser.com
10x Genomics (Nasdaq: TXG) Xenium Powers ASTRA Atlas of 2,000 Asia-Pacific Tumor Samples - Stock Titan
10x Genomics (TXG) Price Target Increased by 10.47% to 16.66 - Nasdaq
10x Genomics Expands Flex Lineup with High-Throughput Single-Cell Assay Launch - MSN
TXG (10x Genomics) Inventory-to-Revenue : 0.44 (As of Sep. 2025) - GuruFocus
10x Genomics Announces Chief Legal Officer Retirement - MSN
10x Genomics GC Who Led Rule Of Law Effort To Retire In '26 - Law360
There's Reason For Concern Over 10x Genomics, Inc.'s (NASDAQ:TXG) Massive 42% Price Jump - simplywall.st
10x Genomics, Inc. Announces Executive Changes, Effective January 1, 2026 - MarketScreener
10X Genomics Stock Soars 17.31%, Hits Intraday High of $15.26 - Markets Mojo
10x Genomics Inc Class A Earnings and Revenue – HAM:1KJ - TradingView
How 10x Genomics Inc. (1KJ) stock valuation compares with sectorChart Signals & Safe Entry Point Alerts - newser.com
Why 10x Genomics Inc. (1KJ) stock attracts wealthy investorsSell Signal & Verified Stock Trade Ideas - newser.com
10x Genomics to Participate in the Wolfe Research Healthcare Conference 2025 - Eastern Progress
5 Insightful Analyst Questions From 10x Genomics's Q3 Earnings Call - Finviz
10x Genomics, Inc. (TXG) Stock Price Quote Today & Current Price Chart - Capital.com
10x Genomics (TXG): Assessing Valuation After Strong Earnings, Upbeat Forecast and New Product Launch - Yahoo Finance
Piper Sandler Maintains 10x Genomics (TXG) Neutral Recommendation - Nasdaq
10x Genomics to Participate in the Wolfe Research Healthcare Con - GuruFocus
10x Genomics (TXG) Soars to New Record High on Lower Net Loss, Revenue Beat - Insider Monkey
Why 10x Genomics (TXG) Stock Is Trading Up Today - Yahoo Finance
Is 10x Genomics Inc. stock ready for a breakoutWeekly Market Summary & AI Enhanced Trading Signals - newser.com
Can a trend reversal in 10x Genomics Inc. lead to recovery2025 Volume Leaders & Real-Time Volume Analysis - newser.com
10x Genomics stock hits 52-week high at 17.26 USD - Investing.com
10x Genomics, Inc.'s (NASDAQ:TXG) 33% Price Boost Is Out Of Tune With Revenues - 富途牛牛
Research Alert: CFRA Keeps Hold Rating On Shares Of 10x Genomics, Inc. - 富途牛牛
10X Genomics Tops Q3 Estimates And Cuts Losses - Finimize
Analysts Offer Insights on Healthcare Companies: 10x Genomics (TXG), Eledon Pharmaceuticals (ELDN) and AMN Healthcare Services (AMN) - The Globe and Mail
10x Genomics (TXG): How Fresh Results and New Guidance Are Shaping Its Valuation - simplywall.st
10x Genomics, Inc. (NASDAQ:TXG) Q3 2025 Earnings Call Transcript - Insider Monkey
Canaccord Genuity Maintains 10x Genomics (TXG) Buy Recommendation - Nasdaq
JP Morgan Maintains 10x Genomics (TXG) Neutral Recommendation - Nasdaq
TXG: Canaccord Genuity Raises Price Target for 10x Genomics to $19 | TXG Stock News - GuruFocus
GUIDANCE: (TXG) 10x Genomics, Inc. Expects Q4 Revenue Range $154.0M$158.0M - 富途牛牛
10x Genomics, Inc. SEC 10-Q Report - TradingView
10x Genomics: Q3 Earnings Snapshot - CT Insider
Is 10x Genomics Inc. stock supported by strong fundamentalsPortfolio Risk Report & Safe Entry Trade Signal Reports - newser.com
10x Genomics Inc (TXG) Q3 2025 Earnings Call Highlights: Navigat - GuruFocus
10 X Genomics Inc Azioni (TXG) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.68%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):